Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and DDI Study of VX-993 with Midazolam, Itraconazole, and Gemfibrozil
NCT06392659Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of VX-993 in pain (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Midazolam at Day 15, Maximum Observed Plasma Concentration (Cmax) of 1-Hydroxy-Midazolam at Day 15 and 6 more. Started May 2024; status: completed.
02
Drugs
VX-993
03
Conditions
pain
Beyond the preview
Go deeper on NCT06392659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06392659.